{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:34:26Z","timestamp":1792974866979,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Pfizer, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40122-016-0048-z","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T09:37:20Z","timestamp":1456825040000},"page":"81-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in China"],"prefix":"10.1007","volume":"5","author":[{"given":"Bruce C. M.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley E.","family":"Furnback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Bifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory F.","family":"Guzauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1097\/00002508-200006001-00017","volume":"16","author":"JA Haythornthwaite","year":"2000","unstructured":"Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16:S101\u20135.","journal-title":"Clin J Pain"},{"key":"48_CR2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11684-014-0355-x","volume":"8","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Feng Y, Qu Z, Qi Y, Zhan S. Current situation and challenge of registry in China. Front Med. 2014;8:294\u20139.","journal-title":"Front Med"},{"issue":"2","key":"48_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejpain.2005.01.014","volume":"10","author":"AM McDermott","year":"2006","unstructured":"McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10(2):127\u201335.","journal-title":"Eur J Pain"},{"issue":"3","key":"48_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpain.2005.05.005","volume":"10","author":"M Vera-Llonch","year":"2006","unstructured":"Vera-Llonch M, Dukes E, Delea TE, Wang ST, Oster G, Neuropathic Pain Outcomes Modeling Working Group. Treatment of peripheral neuropathic pain: a simulation model. Eur J Pain. 2006;10(3):279\u201385 [Epub 2005 Jun 23].","journal-title":"Eur J Pain"},{"issue":"11","key":"48_CR5","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.clinthera.2006.11.017","volume":"28","author":"JE Tarride","year":"2006","unstructured":"Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther. 2006;28(11):1922\u201334.","journal-title":"Clin Ther"},{"issue":"2","key":"48_CR6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3111\/13696998.2011.632797","volume":"15","author":"J Gordon","year":"2012","unstructured":"Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ. 2012;15(2):207\u201318.","journal-title":"J Med Econ."},{"issue":"10","key":"48_CR7","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1185\/030079907X233151","volume":"23","author":"MJ Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez MJ, D\u00edaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin. 2007;23(10):2585\u201396.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"48_CR8","doi-asserted-by":"crossref","first-page":"A660","DOI":"10.1016\/j.jval.2015.09.2395","volume":"18","author":"BC Wang","year":"2015","unstructured":"Wang BC, Liu D, Furnback W, Bifa F, Dong P, Xie L, Zhang S. Assessing the treatment of peripheral neuropathic pain (Pnep) and postherpetic neuralgia (Phn) in China using a simulation model. Value Health. 2015;18(7):A660.","journal-title":"Value Health"},{"key":"48_CR9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"R Freynhagen","year":"2005","unstructured":"Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254\u201363.","journal-title":"Pain"},{"key":"48_CR10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628\u201338.","journal-title":"Pain"},{"issue":"2","key":"48_CR11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118\u201324.","journal-title":"Bull World Health Organ"},{"key":"48_CR12","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"M Backonja","year":"1998","unstructured":"Backonja M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998;280:1831\u20136.","journal-title":"JAMA"},{"key":"48_CR13","doi-asserted-by":"crossref","unstructured":"Rowbotham M, Harden N, Stacey B, et al. for the Gabapentin Postherpetic Neuralgia Study Group. Gabapentin in the treatment of post-herpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837\u201342.","DOI":"10.1001\/jama.280.21.1837"},{"key":"48_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3111\/200609055068","volume":"9","author":"JE Tarride","year":"2006","unstructured":"Tarride JE, Collet JP, Choiniere M, et al. The economic burden of neuropathic pain in Canada. J Med Econ. 2006;9:55\u201368.","journal-title":"J Med Econ."},{"key":"48_CR15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","volume":"6","author":"RW Richter","year":"2005","unstructured":"Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253\u201360.","journal-title":"J Pain."},{"key":"48_CR16","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","volume":"63","author":"H Lesser","year":"2004","unstructured":"Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104\u201310.","journal-title":"Neurology."},{"key":"48_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","volume":"109","author":"R Sabatowski","year":"2004","unstructured":"Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26\u201335.","journal-title":"Pain"},{"key":"48_CR18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","volume":"60","author":"RH Dworkin","year":"2003","unstructured":"Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274\u201383.","journal-title":"Neurology."},{"key":"48_CR19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"R Freynhagen","year":"2005","unstructured":"Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multi- centre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254\u201363.","journal-title":"Pain"},{"issue":"4","key":"48_CR20","doi-asserted-by":"crossref","first-page":"e0121915","DOI":"10.1371\/journal.pone.0121915","volume":"10","author":"B Wang","year":"2015","unstructured":"Wang B, Roth JA, Nguyen H, Felber E, Furnback W, Garrison LP. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. PLoS One. 2015;10(4):e0121915.","journal-title":"PLoS One"},{"key":"48_CR21","first-page":"1989","volume":"11","author":"CF Chiou","year":"2015","unstructured":"Chiou CF, Wang B, Caldwell R, Furnback W, Lee JS, Kothandaraman N, Wang J, Zhang F. The cost reduction in hospitalization associated with paliperidone palmitate in China, Korea, and Malaysia. Neuropsychiatr Dis Treat. 2015;11:1989\u201394.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"48_CR22","volume-title":"Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia in Taiwan","author":"B Wang","year":"2014","unstructured":"Wang B, Fang CH, Furnback W, Kim R, Magyar A, Yang YW. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia in Taiwan. Barcelona: European Society of Clinical Microbiology and Infectious Diseases Meeting; 2014."}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-016-0048-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T04:12:46Z","timestamp":1567656766000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40122-016-0048-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s40122-016-0048-z","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}